» Articles » PMID: 10321575

Herpesviruses--a Rationale for Antiviral Treatment in Multiple Sclerosis

Overview
Journal Antiviral Res
Publisher Elsevier
Date 1999 May 13
PMID 10321575
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In multiple sclerosis (MS), the extensive and long lasting search for viruses or other pathogens has hitherto failed to identify a common etiological agent. However, the beneficial effects by interferon-beta treatment in MS, although suggested to depend mainly on immunomodulation, might lend support to a viral involvement in the pathogenesis. The human herpesviruses have attracted interest since their recurrent modes of infection share some similarity with the relapsing-remitting course of MS, most members are readily detected within the brain, and several of these viruses may induce demyelination within the central nervous system in human hosts as well as in animal models. Accumulated diagnostic and epidemiological data are compatible with a role for the herpesviruses as possible cofactors rather than etiological agents, and recent studies showing early neuronal damage in MS patients focus attention on the neurotropic alpha-herpesviruses. Antiviral treatment trials with safe and effective drugs such as valaciclovir offer a possibility of testing the hypotheses concerning herpesviral involvement in MS.

Citing Articles

Alzheimer's disease and multiple sclerosis: a possible connection through the viral demyelinating neurodegenerative trigger (vDENT).

Boukhvalova M, Kastrukoff L, Blanco J Front Aging Neurosci. 2023; 15:1204852.

PMID: 37396655 PMC: 10310923. DOI: 10.3389/fnagi.2023.1204852.


Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Gilli F, Li L, Royce D, DiSano K, Pachner A J Neurovirol. 2017; 23(6):825-838.

PMID: 28913765 DOI: 10.1007/s13365-017-0570-8.


Isolation and growth of a cytopathic agent from multiple sclerosis brain tissue.

White A, Dutton N, Cook R J Neurovirol. 2002; 8(2):111-21.

PMID: 11935463 DOI: 10.1080/13550280290049543.

References
1.
Lycke J, Andersen O, Svennerholm B, Appelgren L, Dahlof C . Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother. 1989; 24(6):947-54. DOI: 10.1093/jac/24.6.947. View

2.
Aharoni R, Teitelbaum D, Sela M, Arnon R . Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997; 94(20):10821-6. PMC: 23498. DOI: 10.1073/pnas.94.20.10821. View

3.
Bachmann S, Kesselring J . Multiple sclerosis and infectious childhood diseases. Neuroepidemiology. 1998; 17(3):154-60. DOI: 10.1159/000026167. View

4.
Skoldenberg B, Forsgren M, ALESTIG K, Bergstrom T, BURMAN L, Dahlqvist E . Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984; 2(8405):707-11. DOI: 10.1016/s0140-6736(84)92623-0. View

5.
Andersson M, Bergstrom T, Blomstrand C, Hermodsson S, Hakansson C, Lowhagen G . Increasing intrathecal lymphocytosis and immunoglobulin G production in neurologically asymptomatic HIV-1 infection. J Neuroimmunol. 1988; 19(4):291-304. DOI: 10.1016/0165-5728(88)90010-0. View